HDAC Inhibitor Polymorphic Forms and Methods of Use
OwnerStefan Proniukinventor
Life of this patent
Estimating the term…
Abstract
Polymorphic forms of histone deacetylase inhibitors (HDAC) and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns, solubility, stability and other properties.
Claims47
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3A.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3B.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3C.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3D.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3E.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3F.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3G.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3H.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3I.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3J.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 3K.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 5A.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 5B.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 5C.
- An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 5D.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 5E.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 5F.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7A.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7B.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7C.
- An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7D.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7E.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7F.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7G.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 7H.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9A.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9B.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9C.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9D.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9E.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9F.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 9G.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 11A.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 11B.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 11C.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 11D.
An AR-42 crystalline form characterized by the X-ray powder diffraction pattern of FIG. 11E.
A method of making an AR-42 polymorphic form comprising combining AR-42 with a solvent selected from the group consisting of methycyclohexane, isopentyl acetate, n-ethyl tetrahydrofuran-2, trimethylpentane 2,2,4-diisopropyl ether, cumene, dichloroethane 1,2-, toluene, cyclohexanone, cyclohexane, anisole, diethyl carbonate (anyhydrous), octane, tert-butylmethyl ether (anhydrous), dimethoxyethane 1,2-, butyl acetate, absolute ethanol, dioxane, 1,4-, chloroform, methyl-1-propanol 2-, dimethyl-3-butanone 2,2-, hydroxy-4-methyl-2-pentanon 4-, tetrahydrofuran, fluorbenzene, chlorobenzene, acetonitrile, methanol, water, nitromethane, ethylbenzene, dimethyl-4-heptanone, 2,6-, trimethylbenzene 1,2,4-, dimethyl-3-butanone 2,2-, nitromethane, fluorobenzene, dioxane, 1,4, methyltetrahydrofuran, 2-, and pentyl acetate.
Dependencies are inferred from the claim text.